Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo

Journal of Immunology

Volumn 191, Issue 1, 2013, Pages 217-227

  Foy, Kevin Chu ^a   Wygle, Ruthie M ^a   Miller, Megan J ^a   Overholser, Jay P ^a   Bekaii Saab, Tanios ^b   Kaumaya, Pravin T P ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; PEPTIDE VACCINE; PEPTIDOMIMETIC AGENT; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER INHIBITION; CHIMERA; CONTROLLED STUDY; DRUG DESIGN; FEMALE; IMMUNIZATION; IMMUNOGENICITY; LIGAND BINDING; LUNG CANCER; MEASLES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RABBIT; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; EPITOPES, B-LYMPHOCYTE; HUMANS; LIGANDS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; PEPTIDOMIMETICS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RABBITS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VACCINES, SUBUNIT;

EID: 84879614294     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300231     Document Type: Article

References (39)

1. Arteaga, C. L. 2002. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 29(Suppl 14): 3-9. (Pubitemid 35191041)
2. Boerner, J. L., A. Danielsen, and N. J. Maihle. 2003. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp. Cell Res. 284: 111-121. (Pubitemid 36331970)
3. Gluz, O., C. Liedtke, N. Gottschalk, L. Pusztai, U. Nitz, and N. Harbeck. 2009. Triple-negative breast cancer - current status and future directions. Ann. Oncol. 20: 1913-1927.
4. Pintens, S., P. Neven, M. Drijkoningen, V. Van Belle, P. Moerman, M. R. Christiaens, A. Smeets, H. Wildiers, and I. Vanden Bempt. 2009. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1. J. Clin. Pathol. 62: 624-628.
5. Hirsch, F. R., M. Varella-Garcia, P. A. Bunn, Jr., M. V. Di Maria, R. Veve, R. M. Bremmes, A. E. Barón, C. Zeng, and W. A. Franklin. 2003. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21: 3798-3807. (Pubitemid 46606235)
6. Arteaga, C. L., and J. Baselga. 2004. Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 5: 525-531. (Pubitemid 38748914)
7. Brabender, J., K. D. Danenberg, R. Metzger, P. M. Schneider, J. Park, D. Salonga, A. H. Holscher, and P. V. Danenberg. 2001. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin. Cancer Res. 7: 1850-1855. (Pubitemid 32994816)
8. Ferguson, K. M., M. B. Berger, J. M. Mendrola, H. S. Cho, D. J. Leahy, and M. A. Lemmon. 2003. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 11: 507-517. (Pubitemid 36297057)
9. Li, S., K. R. Schmitz, P. D. Jeffrey, J. J. Wiltzius, P. Kussie, and K. M. Ferguson. 2005. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301-311. (Pubitemid 40544648)
10. Sawano, A., S. Takayama, M. Matsuda, and A. Miyawaki. 2002. Lateral propagation of EGF signaling after local stimulation is dependent on receptor density. Dev. Cell 3: 245-257.
11. Grothey, A. 2006. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology (Huntingt.) 20(Suppl 10): 21-28.
12. Kaumaya, P. T., and K. C. Foy. 2012. Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol. 8: 961-987.
13. Burgess, A. W., H. S. Cho, C. Eigenbrot, K. M. Ferguson, T. P. Garrett, D. J. Leahy, M. A. Lemmon, M. X. Sliwkowski, C. W. Ward, and S. Yokoyama. 2003. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12: 541-552. (Pubitemid 37222478)
14. Sundaram, R., N. K. Dakappagari, and P. T. Kaumaya. 2002. Synthetic peptides as cancer vaccines. Biopolymers 66: 200-216. (Pubitemid 35285219)
15. Kaumaya, P. T., S. Kobs-Conrad, Y. H. Seo, H. Lee, A. M. VanBuskirk, N. Feng, J. F. Sheridan, and V. Stevens. 1993. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. J. Mol. Recognit. 6: 81-94. (Pubitemid 2022821)
16. Garrett, J. T., S. Rawale, S. D. Allen, G. Phillips, G. Forni, J. C. Morris, and P. T. Kaumaya. 2007. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J. Immunol. 178: 7120-7131. (Pubitemid 46847438)
17. Borowsky, A. D., R. Namba, L. J. Young, K. W. Hunter, J. G. Hodgson, C. G. Tepper, E. T. McGoldrick, W. J. Muller, R. D. Cardiff, and J. P. Gregg. 2005. Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin. Exp. Metastasis 22: 47-59. (Pubitemid 41185861)
18. Pei, X. F., M. S. Noble, M. A. Davoli, E. Rosfjord, M. T. Tilli, P. A. Furth, R. Russell, M. D. Johnson, and R. B. Dickson. 2004. Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cell. Dev. Biol. Anim. 40: 14-21. (Pubitemid 38756888)
19. Dakappagari, N. K., D. B. Douglas, P. L. Triozzi, V. C. Stevens, and P. T. Kaumaya. 2000. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res. 60: 3782-3789. (Pubitemid 32204569)
20. Kaumaya, P. T., K. C. Foy, J. Garrett, S. V. Rawale, D. Vicari, J. M. Thurmond, T. Lamb, A. Mani, Y. Kane, C. R. Balint, et al. 2009. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J. Clin. Oncol. 27: 5270-5277.
21. Vicari, D., K. C. Foy, E. M. Liotta, and P. T. Kaumaya. 2011. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J. Biol. Chem. 286: 13612-13625.
22. Foy, K. C., Z. Liu, G. Phillips, M. Miller, and P. T. Kaumaya. 2011. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J. Biol. Chem. 286: 13626-13637.
23. Lairmore, M. D., A. M. DiGeorge, S. F. Conrad, A. V. Trevino, R. B. Lal, and P. T. Kaumaya. 1995. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction. J. Virol. 69: 6077-6089.
24. Hruby, V. J. 1993. Conformational and topographical considerations in the design of biologically active peptides. Biopolymers 33: 1073-1082. (Pubitemid 23184442)
25. Allen, S. D., J. T. Garrett, S. V. Rawale, A. L. Jones, G. Phillips, G. Forni, J. C. Morris, R. G. Oshima, and P. T. Kaumaya. 2007. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J. Immunol. 179: 472-482. (Pubitemid 46986564)
26. Allen, S. D., S. V. Rawale, C. C. Whitacre, and P. T. Kaumaya. 2005. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. J. Pept. Res. 65: 591-604. (Pubitemid 40776411)
27. Chua, W., M. Peters, R. Loneragan, and S. Clarke. 2009. Cetuximab-associated pulmonary toxicity. Clin. Colorectal Cancer 8: 118-120.
28. Ocvirk, J. 2010. Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream. Radiol. Oncol. 44: 265-266.
29. Wheeler, D. L., S. Huang, T. J. Kruser, M. M. Nechrebecki, E. A. Armstrong, S. Benavente, V. Gondi, K. T. Hsu, and P. M. Harari. 2008. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27: 3944-3956. (Pubitemid 351913636)
30. Kamat, V., J. M. Donaldson, C. Kari, M. R. Quadros, P. I. Lelkes, I. Chaiken, S. Cocklin, J. C. Williams, E. Papazoglou, and U. Rodeck. 2008. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol. Ther. 7: 726-733.
31. Schmiedel, J., A. Blaukat, S. Li, T. Knöchel, and K. M. Ferguson. 2008. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13: 365-373. (Pubitemid 351446197)
32. Li, S., P. Kussie, and K. M. Ferguson. 2008. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 16: 216-227. (Pubitemid 351215209)
33. Garrett, T. P., A. W. Burgess, H. K. Gan, R. B. Luwor, G. Cartwright, F. Walker, S. G. Orchard, A. H. Clayton, E. C. Nice, J. Rothacker, et al. 2009. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc. Natl. Acad. Sci. USA 106: 5082-5087.
34. Hartmann, C., N. Müller, A. Blaukat, J. Koch, I. Benhar, and W. S. Wels. 2010. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 29: 4517-4527.
35. Balañá, M. E., L. Labriola, M. Salatino, F. Movsichoff, G. Peters, E. H. Charreau, and P. V. Elizalde. 2001. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 20: 34-47.
36. Riemer, A. B., M. Klinger, S. Wagner, A. Bernhaus, L. Mazzucchelli, H. Pehamberger, O. Scheiner, C. C. Zielinski, and E. Jensen-Jarolim. 2004. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J. Immunol. 173: 394-401. (Pubitemid 38797365)
37. Schaefer, G., L. Haber, L. M. Crocker, S. Shia, L. Shao, D. Dowbenko, K. Totpal, A. Wong, C. V. Lee, S. Stawicki, et al. 2011. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20: 472-486.
38. Banappagari, S., M. Corti, S. Pincus, and S. Satyanarayanajois. 2012. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic. J. Biomol. Struct. Dyn. 30: 594-606.
39. Hudis, C. A., and L. Gianni. 2011. Triple-negative breast cancer: an unmet medical need. Oncologist 16(Suppl 1): 1-11.